TJ-L1I7 / NovaBridge Biosciences - LARVOL DELTA

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021 (PRNewswire) - "In addition, other novel bispecific antibodies are currently under pre-clinical development and are expected to advance to the clinical studies in 2022, including: TJ-C4GM is a fortified CD47 antibody with GM-CSF cytokine…TJ-L1C4 belongs to I-Mab's PD-L1 based bispecific antibody family and uses CD47 antibody as the other arm….TJ-L1I7 is an antibody-cytokine fusion protein with the anti-PDL1 antibody fused with IL-7, which is designed to increase both the number and functionality of T cells drawn to the tumor thereby turning ‘cold’ tumor into a more immune-responsive ‘hot’ tumor."

New trial • Oncology • Solid Tumor